Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

This article was originally published here

The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung

The post Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply